Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-31

Study Completion Date

2027-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

NCT05354752

Inflammatory Bowel Diseases

COMPLETED PHASE1

Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects

NCT05138770

Inflammatory Bowel Diseases

COMPLETED PHASE1

Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers

NCT00991016

Healthy Volunteers

TERMINATED PHASE1

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

NCT01897142

Healthy

COMPLETED PHASE1

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

NCT01140672

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-segmental Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VC005 Tablets Low Dose groups

Group Type EXPERIMENTAL

VC005 tablets

Intervention Type DRUG

VC005 groups repeat administration for 52 weeks

VC005 Tablets High Dose groups

Group Type EXPERIMENTAL

VC005 tablets

Intervention Type DRUG

VC005 groups repeat administration for 52 weeks

VC005 Tablets Placebo groups

Group Type PLACEBO_COMPARATOR

VC005 Tablets Placebo

Intervention Type DRUG

VC005 Placebo groups repeat administration for 52 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VC005 tablets

VC005 groups repeat administration for 52 weeks

Intervention Type DRUG

VC005 Tablets Placebo

VC005 Placebo groups repeat administration for 52 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
* The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

Exclusion Criteria

* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
* All hair in the vitiligo area on the face is white.
* Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
* Subjects who have previously received depigmentation treatment.
* Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No